Navigation Links
R&D Trends: Depression - Clinical attrition driven by mature market conditions
Date:3/22/2012

opular approaches include glutamate and neuropeptide receptor modulation. Datamonitor sees the future of treatment in depression as the specific targeting of treatment-resistant patients.Clinical trial design in depression is largely standardized. Although not required, head-to-head trials may allow for a more favorable label and explicit marketing claims. Datamonitor believes that future trials will be designed for regulatory approval in patients with treatment-resistant depression, or for use as an add-on to existing therapies.What are the key trends in the depression pipeline?What is the clinical gold standard and how do new candidates have to compare to this to successfully penetrate the market?How will new antidepressant treatments evolve in the next 20 years?

 

 

 

OVERVIEW

Catalyst

Summary

EXECUTIVE SUMMARY

Strategic scoping and focus

Update details: January 2012

Datamonitor key findings

Related reports

CLINICAL PIPELINE OVERVIEW

Overview of the depression pipeline

Datamonitor has identified 46 separate programs in clinical development

Emerging features of the depression pipeline

Changes in pipeline dynamics

Companies involved in the depression pipeline

Discontinued pipeline drugs in depression

54 distinct depression projects have been discontinued since 2010

The vast majority of discontinuations happen either during preclinical testing or Phase II studies

Neuropeptide modulators and monoamine reuptake inhibitors head the list of discontinued projects

TARGET PRODUCT PROFILE

Comparator therapies

Lexapro (escitalopram; Forest/Lundbeck)

Target product profile versus current level of attainment

CLINICAL TRIAL DESIGN IN DEPRESSION

Clinical trials

Commonly used clinical trial endpoints for depression

Typical trial design

Trial length is commonl
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
2. LOREAL and Hurel Corporation Announce R&D Collaboration to Develop a Non-Animal Alternative, Microfluidic Biochip
3. Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
4. R&D Investment by U.S. Biopharmaceutical Companies Remains Strong Despite Ongoing Economic Challenges
5. R&D Investment by U.S. Biopharmaceutical Companies Increases to Record $65.3 Billion, Study Finds
6. Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten Notable People in R&D
7. Gelesis Unveils Novel Non-Invasive Capsulated Device for Obesity and Presents Clinical Data; Appoints Former Pfizer R&D President to Board
8. NeoStem, Inc. Officially Launches Adult Stem Cell Collection Center and R&D Laboratory in Cambridge, Massachusetts
9. Global Pharmaceutical R&D Productivity Declining According to Thomson Reuters, CMR International
10. Pfizer Inc and GoIndustry DoveBid Partner to Auction Surplus Equipment from R&D Facilities Across the United States
11. Orthocare Innovations Receives Prestigious R&D 100 Award for Novel Web-Based Rehabilitation Outcomes Assessment System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... 2014 The Cadence Fitness & Health Center has ... Medical Fitness Association, a non-profit organization assisting medically integrated ... The Cadence Fitness & Health Center is the only ... in the Chicagoland area. "The certification means ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Boston Scientific Corporation (NYSE: BSX ) ... quality of life outcomes, based on one-year data from ... while the overall cost effectiveness of percutaneous coronary intervention ... according to patient characteristics, PCI was more cost effective ...
... to be presented at Israel Society of ... reach 5 months from single treatment - Data ... scores of expensive injections MISGAV, Israel and LONDON, March ... that the latest, encouraging results of the Company,s ongoing ...
Cached Medicine Technology:SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 2SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 3SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease 5Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 2Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 3Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients 4
(Date:4/17/2014)... its status as the leading weapon against the deadly ... with new research indicating it simply needs to be ... of the cheap anti-malarial drug chloroquine in treating and ... more than half a million people each year around ... developed resistance to chloroquine, but research carried out at ...
(Date:4/16/2014)... April 15, 2014 The Translational Genomics Research Institute ... annual Founders Dinner for their support of TGen,s research ... place March 28 in Scottsdale. , Catherine Ivy, Founder ... received TGen,s John S. McCain Leadership Award, named for ...
(Date:4/16/2014)... April 16, 2014 According to a new study, ... patients with one to two small polyps are consistent ... This may be an appropriate target for quality indicators. ... quantify adherence to guidelines for timing of repeat colonoscopy ...
(Date:4/15/2014)... frozen fish caused nearly half of all injuries aboard ... on freezer-longliner vessels operating off the coast of Alaska, ... of those injuries and others aboard the two types ... and the research methods used in the study could ...
(Date:4/15/2014)... the University of California, San Diego School of Medicine have ... C virus get liver disease and why the virus is ... , The hard-to-kill pathogen, which infects an estimated 200 million ... mitochondria dismantling the cell,s innate ability to fight infection. ...
Breaking Medicine News(10 mins):Health News:Scientists find new way to fight malaria drug resistance 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Changes in processing, handling could reduce commercial fishing injuries 2Health News:Breaking bad mitochondria 2
... Favorite, and ,Have Fun Helping It ... ... Recession? Killer bees? No! Only positive predictions, please.,That,s the attitude of Richard ... debut last month., *(PHOTO 72dpi: Send2Press.com/mediaboom/07-1115-DSamson_72dpi.jpg), *(Photo Caption: SuperLife founder ...
... /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. (OTC Bullion ... medicinal and diagnostic products in China,today announced that ... Company,s Form 10QSB for the fiscal quarters ended ... filed its full year 2006 amendments on,November 8, ...
... 18 Escalon Medical Corp.,(Nasdaq Capital Market: ESMC) ... clearance from the U.S. Food and Drug,Administration (FDA) ... differential Hematology Analyzer. Drew Scientific plans to,commence shipments ... month-end., "The FDA clearance represents a major ...
... PHILADELPHIA A new brain imaging study by researchers ... Pennsylvania shows that cigarette cravings in smokers who are ... specific regions of the brain. Using a novel method ... MD, associate professor of Neurology at Penn, this study ...
... (NYSE: CDI ),announced today that the Life ... been awarded a contract from CJ CheilJedang,Corporation to ... manufacturing complex to be located in Osong, Korea. ... center for global,distribution of oral solid and sterile ...
... where he worked as a ... ... Dikembe,Mutombo, who is known as much for his philanthropy as his storied ... organization prepare its entry into his home country, the,Democratic Republic of Congo ...
Cached Medicine News:Health News:Six Positive Predictions for 2008, from SuperLife World Service 2Health News:China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006 2Health News:Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System 2Health News:Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System 3Health News:New neuroimaging study identifies 'brain signature' for cigarette cravings 2Health News:CDI-Life Sciences Selected by CJ CheilJedang Corp. to Provide Engineering Design for Major Pharmaceutical Complex in Korea 2Health News:NBA Legend Dikembe Mutombo Joins Opportunity International Board of Advisors; Opens Doors in Democratic Republic of Congo 2Health News:NBA Legend Dikembe Mutombo Joins Opportunity International Board of Advisors; Opens Doors in Democratic Republic of Congo 3Health News:NBA Legend Dikembe Mutombo Joins Opportunity International Board of Advisors; Opens Doors in Democratic Republic of Congo 4